Methicillin-resistant Staphylococcus aureus (MRSA) is one of the leading pathogens for hospital and community-acquired infections. Increased use of Vancomycin has resulted in the emergence of MRSA with reduced susceptibility to Vancomycin. The emergence of Vancomycin-intermediate or resistant S. aureus has created the need for other anti MRSA antibiotics. To isolate the Staphylococcus aureus from various clinical samples, determine the prevalence of MRSA and to assess the in-vitro susceptibility of Daptomycin against MRSA isolates. A total of 418 clinical samples like pus, blood, urine, sputum, body fluids; received from various departments in the department of microbiology were included in the study. All samples were processed for Staphylococcus aureus isolates. Methicillin resistance was identified in all isolates by using Cefoxitin disc diffusion method. Susceptibility and MIC of Daptomycin against MRSA was determined by E (Epsilometer) test method. Out of 418 clinical samples, 126 () were Staphylococcus aureus. Out of 126 , 50() were MRSA. Susceptibility and MIC of Daptomycin were determined by E-Test method in all MRSA isolates. All (100%) MRSA isolated were susceptible to Daptomycin with MIC range to µg /ml. Daptomycin showed 100% sensitivity against all MRSA isolates in our study. Suggesting Daptomycin can be used as alternative agents for the treatment of infections caused by MRSA.
